Metformin, a widely prescribed medication for managing type 2 diabetes, has demonstrated potential in slowing down the aging process of vital organs, according to a new study conducted on primates. The research, carried out in China, suggests that daily doses of metformin can significantly reduce the rate of aging in kidneys, lungs, skin, and even the brain. These findings could pave the way for future human trials to explore metformin's anti-aging properties in humans.
Impact on Organ Aging
The study focused on middle-aged male monkeys, with some receiving a daily dose of metformin over a three-year period. The results indicated that the monkeys treated with metformin experienced a notable slowdown in the aging of several key organs. Specifically, the kidneys, lungs, and skin aged up to five years slower, while the brain showed a reduction in aging of up to six years. This suggests a systemic effect of metformin on multiple organ systems.
Potential for Human Trials
The researchers are optimistic about the potential for translating these findings to human health. The next step involves conducting human trials to determine whether metformin can indeed slow down aging in people. If successful, this could have profound implications for preventing age-related diseases and extending healthy lifespan.
Metformin's Role in Diabetes Management
Metformin is typically the first-line medication prescribed to manage blood sugar levels in individuals with type 2 diabetes. Its primary function is to improve insulin sensitivity and reduce glucose production in the liver. The drug is administered orally and is considered a safe and effective treatment option for diabetes. While previous studies in lower-order species have hinted at its potential to delay age-related diseases, this new study provides more compelling evidence in primates, bringing it closer to potential human applications.
